Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

AlloVir, Inc. ALVR NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

AlloVir, Inc. (ALVR) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 4 Buy, 2 Hold, 2 Sell.

ALVR Analyst Ratings

Buy
8
Ratings
4 Buy
2 Hold
2 Sell
Based on 8 analysts giving stock ratings to AlloVir, Inc. in the past 3 months
Rating breakdown
Buy
4 50%
Hold
2 25%
Sell
2 25%
50%
Buy
4 analysts
25%
Hold
2 analysts
25%
Sell
2 analysts

People Also View

MRUS
MRUS
Merus N.V.
$90.00
+0.00%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 AGIO
AGIO
Agios Pharmaceuticals, Inc.
$33.30
+0.45%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.19
+7.40%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message